Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AXT Inc (AXTI) vs BioNTech SE - ADR (BNTX) Price & Performance

BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

AXT Inc vs BioNTech SE - ADR — how do they compare? AXT Inc trades at $79.45 (market cap $4.83B), while BioNTech SE - ADR trades at $93.32 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 4.8× AXT Inc's market cap, and AXT Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

AXTIBNTX
Market Cap
$4.83B$23.31B
Sector
TechnologyHealth
52-Week High
$140.83$119.34
52-Week Low
$2.05$83.89
Enterprise Value
$4.50B$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AXT Inc

AXTI trades at $79.75, up 8.05% on the day, reflecting strong momentum following Q2 2026 earnings that beat estimates with EPS of $0.19 versus $0.07 expected. The stock is in a bullish technical trend, with support near $72 and resistance at $79. Revenue surged to $126 million in 2026, driving a net profit of $4 million and margin expansion to 3.23%, supported by record indium phosphide demand for AI data centers.

Outlook is positive given AI-driven demand and capacity expansion, but high valuation ratios (P/S 30.53) and negative operating cash flow pose risks. Analyst consensus is bullish with a $72.50 price target, though the current price exceeds it, suggesting near-term consolidation may occur.

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AXT Inc

AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.

Read more on AXTI

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX